Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00352911 · ClinicalTrials.gov registry record · Phase 2
Antiviral Activity and Safety of Mifepristone at 2 Doses in HIV-1 Infected Subjects
A Phase 2 study of HIV Infections, sponsored by VGX Pharmaceuticals.
- Completed
- Registry status
- Phase 2
- Development phase
- 19
- Enrollment target
- 3
- Study locations
NCT00352911: Completed Phase 2 study of HIV Infections, sponsored by VGX Pharmaceuticals.
NCT00352911 is a Phase 2 study of HIV Infections that has completed, run by VGX Pharmaceuticals. The registered enrollment target is 19 participants, below the 446-participant average among 542 other HIV Infections trials with a reported enrollment target (96% lower). The trial reports 3 study locations across 2 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00352911, a Phase 2 study of HIV Infections, has completed, sponsored by VGX Pharmaceuticals.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 19 participants
- Enrollment target
- 3
- Study locations
Study Summary
The objective of the study is to determine whether mifepristone (VGX-410) has anti-HIV-1 activity at doses of either 300 mg or 600 mg per day after oral administration for 14 days at each dose level.
Conditions Studied
Interventions
- DRUG VGX-410 (Mifepristone)
- DRUG Placebo for VGX-410 (Mifepristone)
Study Locations (3)
Pennsylvania
- University of Pennsylvania - Philadelphia
- Veterans Hospital of Philadelphia - Philadelphia
District of Columbia
- Georgetown University - Washington D.C.
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 19 participants |
| Start Date | 2006-07 |
| Est. Completion | 2007-11 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00352911
The ClinicalTrials.gov registry entry for NCT00352911 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 19 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 446-participant average among 542 other HIV Infections trials with a reported enrollment target (96% lower). The listed sponsor is VGX Pharmaceuticals, which has 4 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with HIV Infections appearing as the primary indexed condition, and to 2 interventions - of which VGX-410 (Mifepristone) is the first listed.
NCT00352911 reports 3 study locations spanning 2 distinct geographic areas - top geographies include Pennsylvania, District of Columbia.
Frequently Asked Questions
What is clinical trial NCT00352911 about?
NCT00352911 is a clinical study titled "Antiviral Activity and Safety of Mifepristone at 2 Doses in HIV-1 Infected Subjects". The objective of the study is to determine whether mifepristone (VGX-410) has anti-HIV-1 activity at doses of either 300 mg or 600 mg per day after oral administration for 14 days at each dose level.
What is the current status of trial NCT00352911?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 19 participants. The study started on 2006-07. Estimated completion is 2007-11.
What conditions does trial NCT00352911 study?
This clinical trial studies the following conditions: HIV Infections.
What interventions are being tested in trial NCT00352911?
The interventions under investigation include: VGX-410 (Mifepristone) (DRUG), Placebo for VGX-410 (Mifepristone) (DRUG).
Who is sponsoring clinical trial NCT00352911?
This trial is sponsored by VGX Pharmaceuticals, which has 4 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00352911 being conducted?
This trial has 3 study locations across District of Columbia, Pennsylvania. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for HIV Infections
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
A Phase 2b Study Evaluating Oral VH4524184 Regimens in Treatment Naïve Persons With HIV-1 (INNOVATE Study)
RECRUITING · Phase 2
-
Microbiome Metabolites and Alcohol in HIV to Reduce CVD RCT
RECRUITING · Phase 2
-
Cholesterol and Inflammation Lowering Via Bempedoic Acid, an ACL-inhibiting Regimen in HIV Trial (CLEAR HIV Trial)
RECRUITING · Phase 2
-
Imaging Immune Activation in HIV by PET-MR
RECRUITING · Phase 2
-
A Study to Evaluate the Pharmacokinetics, Safety, and Tolerability of a New Formulation of Cabotegravir Long-Acting Administered Intramuscularly in a 4-month Dosing Interval (Q4M)
ACTIVE NOT RECRUITING · Phase 2
-
A Study to Investigate the Virologic Efficacy and Safety of VH3810109 + Cabotegravir Compared to Standard of Care (SOC) in Male and Female Adults Living With Human Immunodeficiency Virus (HIV)
ACTIVE NOT RECRUITING · Phase 2
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.